REGEN BIOPHARMA, INC. (RGBPP) Net margin 2017–2025
REGEN BIOPHARMA, INC. (RGBPP) net profit margin by fiscal year — reported net income divided by reported revenue.
-282.5%FY2025 · since FY2017: -7046.0% → -282.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -282.5% | -771.4 pp |
| FY2024 | 488.9% | -544.1 pp |
| FY2023 | 1032.9% | +6422.8 pp |
| FY2022 | -5389.9% | -10969.6 pp |
| FY2021 | 5579.7% | +7964.4 pp |
| FY2020 | -2384.7% | +1901.8 pp |
| FY2019 | -4286.5% | +1552.5 pp |
| FY2018 | -5839.0% | +1207.0 pp |
| FY2017 | -7046.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBPP financial trends
RGBPP RevenueRGBPP Net incomeRGBPP Gross profitRGBPP Gross marginRGBPP Operating incomeRGBPP Operating marginRGBPP Operating cash flowRGBPP Free cash flowRGBPP Capital expendituresRGBPP Return on equityRGBPP Stock buybacksRGBPP Dividends paidRGBPP Total assetsRGBPP Total liabilitiesRGBPP Shareholders’ equityRGBPP overview →